Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Alisertib in Advanced Cancer with Hepatic Impairment
NCT02214147Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Aug 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of alisertib in solid tumor (advanced stage) and lymphoma (3 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration for Unbound Alisertib, Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Concentration for Unbound Alisertib and 1 more. Started Aug 2014; status: completed.
02
Drugs
alisertib
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT02214147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02214147.